CATALYST FINANCIAL PARTNERS LLC
Position in REGN — Regeneron Pharmaceuticals, Inc.
CIK 1927537
BOSTON, MA
Position in REGN
as of Jun 30, 2026
· filed Jul 30, 2026
Position Value
$221,356
-$135,603 QoQ
Shares Held
355
-23.2% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#1,024
of 1,322 holders
Holding Since
Sep 2023
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in REGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CATALYST FINANCIAL PARTNERS LLC holds $1,897,610 across 5 Biotechnology names. REGN ranks #5 (11.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,320 | $655,683 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
2,725 | $510,338 | |
| 3 | DMAC |
DiaMedica Therapeutics Inc.
|
38,457 | $270,737 | |
| 4 | ABOS |
Acumen Pharmaceuticals, Inc.
|
89,699 | $239,496 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
This page
|
355 | $221,356 |
All Filings in REGN
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $221,356 | 355 | Shares | Sole | 2026-07-30 | |
| 2026-03-31 | $356,959 | 462 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $317,238 | 411 | Shares | Sole | 2026-02-04 | |
| 2024-12-31 | $230,082 | 323 | Shares | Sole | 2025-01-30 | |
| 2024-09-30 | $345,857 | 329 | Shares | Sole | 2024-10-28 | |
| 2024-06-30 | $342,635 | 326 | Shares | Sole | 2024-07-25 | |
| 2024-03-31 | $302,221 | 314 | Shares | Sole | 2024-04-23 | |
| 2023-12-31 | $259,095 | 295 | Shares | Sole | 2024-02-07 | |
| 2023-09-30 | $235,366 | 286 | Shares | Sole | 2023-10-26 | |
| No filing history on record for this holder in this stock. | ||||||